NCT03537911 is a NA clinical trial of Cognitive Support Program in Metastases, CNS, sponsored by University Health Network, Toronto.

Who is sponsoring NCT03537911?

NCT03537911 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT03537911?

Interventions in NCT03537911: Cognitive Support Program.

What condition does NCT03537911 study?

NCT03537911 studies Metastases, CNS.

Is NCT03537911 still recruiting?

NCT03537911 is currently completed. Last updated 17 April 2019.

Last reviewed 2019-04-17 · How we verify

NCT03537911

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cognitive Support Program for Patients With Brain Metastases

Completed NA Last updated 17 April 2019

What this trial tests

NA trial testing Cognitive Support Program in Metastases, CNS in 18 participants. Completed in 28 November 2018.

Timeline

1 July 2017

Primary endpoint
28 November 2018

28 November 2018

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	18
Start date	1 July 2017
Primary completion	28 November 2018
Estimated completion	28 November 2018
Sites	1 location across Canada

Drugs / interventions tested

Cognitive Support Program

Conditions studied

Metastases, CNS — all drugs for Metastases, CNS →

Sponsor

University Health Network, Toronto

Who can join

Adults 18 to 90, any sex, with Metastases, CNS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the feasibility and preliminary efficacy of a brief cognitive-behavioural program designed to improve cognitive functioning in people with brain metastases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03537911 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 17 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03537911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing